New research sits at the center of this dementia and brain health question.

Researchers have discovered that examining tissue from the olfactory cleft—the narrow space in the upper nasal cavity where smell receptors originate—can reveal Alzheimer’s disease pathology at all stages of the disease, from preclinical (before symptoms appear) through clinical Alzheimer’s. This finding, published in Nature Communications in 2026, demonstrates that the changes associated with Alzheimer’s disease don’t occur only in the brain; they also manifest in nasal tissue in ways that are measurable, consistent, and correlate with the severity of cognitive decline. The study analyzed cellular and molecular markers in the olfactory mucosa of 22 subjects, including cognitively normal individuals, people with positive biomarkers indicating preclinical Alzheimer’s, and those with diagnosed Alzheimer’s disease.

This article explores what the research reveals about this minimally invasive diagnostic approach, how it works, what limitations remain, and what it could mean for earlier detection and monitoring of Alzheimer’s disease. The potential clinical significance is substantial because the olfactory biopsy is far simpler than traditional methods of detecting Alzheimer’s pathology. Rather than waiting for cognitive symptoms to emerge or relying on expensive brain imaging and cerebrospinal fluid sampling, clinicians may eventually be able to perform a routine nasal biopsy during an outpatient visit to identify Alzheimer’s-related changes long before memory problems appear. This could reshape how we think about diagnosing and monitoring Alzheimer’s disease, potentially allowing interventions to begin earlier when treatments might have the greatest impact.

What Is Olfactory Cleft Biopsy and How Does It Reveal Alzheimer’s Pathology?
Neuroinflammatory Markers Detected Across Disease Stages
Study Design and Sample Population
Clinical Applications and Diagnostic Potential
Limitations, Uncertainties, and Considerations
How Olfactory Biopsy Compares to Other Alzheimer’s Biomarkers
Future Research Directions and Clinical Translation
Conclusion

What Is Olfactory Cleft Biopsy and How Does It Reveal Alzheimer’s Pathology?

The olfactory cleft is the uppermost part of the nasal cavity, where olfactory neurons and supporting glial cells constantly detect and transmit smell signals to the brain. For decades, neuroscientists have known that the olfactory system is among the first regions affected in Alzheimer’s disease—many people experience a loss of smell years before memory problems emerge. However, most research focused on the olfactory bulb and related brain structures, not the nasal tissue itself. The new research takes a different approach: it examines the olfactory mucosa (the tissue lining the olfactory cleft) directly using a minimally invasive endoscopically-guided cytology brush biopsy.

During a routine outpatient procedure, physicians can gently brush cells from the olfactory mucosa and then analyze these cells using advanced single-cell RNA-sequencing technology, which identifies the genes being expressed in individual cells and reveals the molecular state of the tissue. The study’s researchers found that the olfactory mucosa in Alzheimer’s disease patients shows specific patterns of neuroinflammation and cellular stress that mirror those observed in brain regions classically associated with memory loss and cognitive decline, such as the hippocampus and entorhinal cortex. This discovery is significant because it suggests the nasal tissue “sees” the same pathological processes occurring in the brain, making it a potential window into disease status. However, a crucial limitation is that the olfactory mucosa changes may not be specific to Alzheimer’s disease alone; other neuroinflammatory conditions or infections affecting the nasal passages could potentially cause similar changes, so any diagnostic application would need to be used alongside other established biomarkers rather than as a standalone test.

What Is Olfactory Cleft Biopsy and How Does It Reveal Alzheimer's Pathology?

Neuroinflammatory Markers Detected Across Disease Stages

The key cellular finding from the research is the presence of activated CD8 memory T cells and inflammatory myeloid cell programs in the olfactory mucosa. These immune cells, which are normally involved in fighting infections and clearing cellular debris, were found to be abnormally active and accumulated in greater numbers in people with Alzheimer’s disease compared to cognitively normal controls. Remarkably, these same activated immune cell signatures were also detectable in cognitively normal individuals who had tested positive for Alzheimer’s-related biomarkers in their cerebrospinal fluid—meaning they were in the preclinical stage of the disease, months or years before cognitive symptoms would appear. This finding is important because it suggests these immune changes occur early in the disease process, potentially before irreversible cognitive damage accumulates.

The magnitude of these immune changes was dose-related in a clinically meaningful way: the neuroinflammatory markers were most pronounced in people with symptomatic Alzheimer’s disease, moderate in those at preclinical stages, and minimal in cognitively normal individuals without Alzheimer’s biomarkers. Additionally, the abundance of amyloid-beta deposits in the olfactory mucosa correlated directly with the severity of cognitive decline—individuals with more amyloid-beta showed greater memory and thinking problems. This correlation suggests that what researchers observe in the nasal tissue genuinely reflects disease severity in the brain. The important caveat is that correlation does not equal causation; the olfactory changes may be a marker of what’s happening systemically without being the primary driver of cognitive decline.

Study Design and Sample Population

The research was conducted as a comprehensive single-cell RNA-sequencing analysis involving olfactory cleft tissue from 22 subjects carefully selected to represent the full spectrum of Alzheimer’s disease. The cohort included three groups: cognitively normal individuals with no evidence of Alzheimer’s pathology (controls), people with cognitive impairment and cerebrospinal fluid biomarker evidence of advanced Alzheimer’s disease (clinical AD), and cognitively normal individuals whose cerebrospinal fluid biomarkers were positive for amyloid-beta and phosphorylated tau but who had not yet developed memory or thinking problems (preclinical AD). This staged design was deliberate—it allowed the researchers to track how olfactory tissue changes evolved across the disease timeline, from the earliest detectable molecular changes through to symptomatic disease.

The use of single-cell RNA-sequencing is particularly powerful because it reveals the gene expression profile of individual cells rather than averaging across thousands of cells, allowing researchers to identify subpopulations of immune cells and neurons that might otherwise be overlooked. The small sample size of 22 subjects, while sufficient for this type of detailed molecular analysis, is a limitation for any broader generalizations. Larger studies in more diverse populations would be needed to confirm whether these olfactory findings hold up consistently across different age groups, ethnicities, and geographic regions, and to establish whether the relationship between olfactory pathology and cognitive decline remains stable over time.

Clinical Applications and Diagnostic Potential

If validated in larger clinical studies, olfactory cleft biopsy could support Alzheimer’s disease diagnosis in several practical ways. Currently, definitive Alzheimer’s diagnosis requires evidence of brain amyloid and tau pathology, which can be detected through expensive positron emission tomography (PET) imaging, amyloid-related imaging abnormalities (ARIA) on MRI, or cerebrospinal fluid biomarker testing (which requires a lumbar puncture, an invasive procedure with risks including infection and headache). An olfactory biopsy would be far simpler—a 10-minute outpatient procedure requiring only topical anesthesia and no sedation, making it feasible for routine clinic visits. A patient with memory concerns could potentially receive an olfactory biopsy along with standard cognitive testing, and the results could help guide whether further expensive testing or disease-modifying therapy is appropriate.

The research also suggests olfactory biopsy could support patient selection and monitoring for disease-modifying therapies. New Alzheimer’s treatments like lecanemab and donanemab work by clearing amyloid-beta but carry significant risks, including amyloid-related imaging abnormalities that can cause brain microhemorrhages or microinfarcts. These treatments are most effective in the earliest stages of cognitive decline and in people with documented amyloid and tau pathology. An accessible biomarker like olfactory biopsy could help clinicians identify which patients truly have underlying Alzheimer’s pathology (as opposed to cognitive changes from other causes like depression, sleep apnea, or medication side effects) before committing them to long-term, potentially risky immunotherapy. However, one critical trade-off to consider is that no single biomarker perfectly predicts who will progress to symptomatic disease; some people with preclinical biomarker evidence never develop cognitive symptoms, so a positive olfactory biopsy would need to be interpreted cautiously rather than automatically triggering treatment.

Limitations, Uncertainties, and Considerations

While the Nature Communications study is well-designed and the findings are promising, several significant limitations must be acknowledged. First, the study was conducted at a single institution with only 22 subjects, which is appropriate for detailed molecular characterization but insufficient for establishing clinical utility or predicting which individual patients would benefit from testing or treatment. The olfactory changes, while consistent with patterns seen in the brain, have not been proven to be specific to Alzheimer’s disease; individuals with other neurodegenerative diseases, chronic rhinosinusitis, or even significant allergic rhinitis might show similar immune activation in nasal tissue.

Additionally, the study did not follow subjects over time to determine whether olfactory changes predict future cognitive decline—it is cross-sectional (all observations made at a single point in time), so we cannot yet know whether a person with preclinical biomarkers and olfactory changes will definitely progress to symptomatic Alzheimer’s within a particular timeframe. The practical implementation of olfactory biopsy also raises questions that the current research does not address. Would the procedure need to be performed by a neuroendocrinologist or ENT specialist, or could it be done in a primary care setting? How would results be standardized across different laboratories and institutions? What threshold of neuroinflammatory markers would indicate “positive” results? Would insurance companies cover the test, and at what cost? The research establishes proof-of-concept, but turning it into a widely available, reliable, standardized clinical tool would require significant additional work. Anyone considering such testing in the near future should recognize that this is still an experimental procedure and should discuss with their neurologist whether it adds meaningful diagnostic information beyond established biomarker testing.

Limitations, Uncertainties, and Considerations

How Olfactory Biopsy Compares to Other Alzheimer’s Biomarkers

The emerging Alzheimer’s biomarker landscape includes several established and newer approaches, each with distinct advantages and limitations compared to olfactory biopsy. Cerebrospinal fluid biomarkers (amyloid-beta 42, phosphorylated tau, and phosphorylated tau-217) are highly accurate and are considered gold-standard markers, but they require lumbar puncture, which carries small risks of infection, headache, and spinal nerve injury, and may not be feasible for frail or elderly patients. Blood biomarkers, particularly plasma phosphorylated tau and phosphorylated tau-217, have emerged in recent years and are increasingly accurate; they require only a blood draw and no special expertise, making them far more accessible than either cerebrospinal fluid sampling or olfactory biopsy. PET imaging shows regional patterns of amyloid and tau deposition in the brain with excellent specificity but is expensive (often $3,000–$5,000 per scan), requires specialized equipment, involves radiation exposure, and is not available in many communities.

Olfactory biopsy sits somewhere in the middle of this spectrum. It is more invasive than a blood draw but less invasive than lumbar puncture or PET imaging. It theoretically provides cellular and tissue-level information (showing which specific immune and neuronal cell types are affected) that blood biomarkers might miss, but it remains unproven in clinical practice and would require specialized equipment and trained personnel to perform and interpret. For a patient with suspected Alzheimer’s disease today, plasma phosphorylated tau blood tests are often the first choice because they are widely available, minimally invasive, highly accurate, and covered by most insurance. Olfactory biopsy might eventually serve a complementary role—perhaps in patients where blood tests are inconclusive, or in research settings aiming to understand the biological mechanisms of Alzheimer’s more deeply—but it is unlikely to replace blood or cerebrospinal fluid biomarkers as the primary diagnostic tool.

Future Research Directions and Clinical Translation

For olfactory cleft biopsy to move from research finding to clinical utility, several important next steps are needed. Multicenter, larger studies enrolling hundreds of subjects from diverse geographic regions and ethnic backgrounds would be necessary to confirm the consistency of these findings and to identify reliable biomarker thresholds that distinguish disease stages. Longitudinal studies following individuals over years would establish whether olfactory changes predict future cognitive decline and at what timeframe. Research comparing olfactory biopsy results to other established biomarkers (plasma phosphorylated tau, cerebrospinal fluid markers, PET imaging) in the same individuals would clarify the relative diagnostic accuracy and utility of the olfactory approach. Additionally, mechanistic studies investigating why the olfactory mucosa mirrors brain pathology in Alzheimer’s disease—whether it is because olfactory neurons are inherently vulnerable to Alzheimer’s pathology, or because systemic inflammation affects nasal tissue, or for some other reason—could illuminate the biological pathways involved in the disease.

The path from research discovery to clinical implementation is typically long and uncertain. Even if larger studies confirm the current findings, it may be several years before olfactory biopsy is offered outside research settings, and only then if health systems determine it fills a genuine clinical need and offers advantages over existing tests. However, the discovery that Alzheimer’s pathology is reflected in minimally invasive nasal tissue is scientifically significant because it opens a new window into the disease process. It validates decades of research suggesting the olfactory system is uniquely vulnerable in Alzheimer’s disease and demonstrates that this vulnerability manifests at a cellular and molecular level even in preclinical stages. As the field continues to develop earlier and more accessible biomarkers for Alzheimer’s disease, the olfactory biopsy approach may eventually contribute to a more comprehensive, multi-modal diagnostic toolkit.

Conclusion

The 2026 Nature Communications study demonstrating a clear relationship between olfactory cleft pathology and Alzheimer’s disease across disease stages represents a meaningful scientific advance. By showing that Alzheimer’s-related cellular changes—including activated immune cells and amyloid-beta accumulation—are detectable in nasal tissue and correlate with cognitive decline, the research identifies a new potential diagnostic window into the disease. The findings are consistent, the methodology is sound, and the implications for minimally invasive, accessible biomarker testing are significant.

However, it is important to recognize that this is early-stage research; the study’s small sample size, single-center design, and lack of longitudinal follow-up mean that many questions remain about clinical applicability, reliability, and utility compared to existing tests. For individuals concerned about cognitive changes or Alzheimer’s disease risk, the most practical immediate step is to discuss memory concerns with a primary care physician or neurologist and ask about blood biomarker testing (such as plasma phosphorylated tau), which is currently available, minimally invasive, and increasingly reliable. Olfactory cleft biopsy may eventually become part of the diagnostic toolkit, but that day is likely years away. In the meantime, this research contributes to a deeper understanding of how Alzheimer’s disease manifests across the body, reinforces the importance of early detection, and demonstrates that scientists continue to develop new approaches to catch the disease before irreversible cognitive damage occurs—offering cautious hope for individuals at risk.